Edition:
India

Tyme Technologies Inc (TYME.OQ)

TYME.OQ on NASDAQ Stock Exchange Capital Market

2.12USD
17 Apr 2018
Change (% chg)

$-0.07 (-3.20%)
Prev Close
$2.19
Open
$2.18
Day's High
$2.19
Day's Low
$2.12
Volume
9,274
Avg. Vol
61,552
52-wk High
$9.50
52-wk Low
$2.01

Chart for

About

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to... (more)

Overall

Beta: --
Market Cap(Mil.): $464.92
Shares Outstanding(Mil.): 89.32
Dividend: --
Yield (%): --

Financials

BRIEF-Tyme Technologies prices offering of 9 mln shares at $2.25 a share

* TYME TECHNOLOGIES ANNOUNCES PRICING OF ITS OFFERING OF 9 MILLION SHARES OF COMMON STOCK

02 Mar 2018

BRIEF-Tyme Technologies Appoints Tommy Thompson To Board Of Directors

* TYME TECHNOLOGIES APPOINTS TOMMY G. THOMPSON TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Tyme Technologies Says To Report Full Phase II Data For SM-88 In Second Half Of 2018

* TYME TECHNOLOGIES INC SAYS LOOK FORWARD TO REPORTING FULL PHASE II DATA FOR SM-88 IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

08 Feb 2018

BRIEF-Tyme Provides Clinical And Corporate Update For Fiscal Q3 2017

* TYME PROVIDES CLINICAL AND CORPORATE UPDATE FOR FISCAL THIRD QUARTER 2017

07 Feb 2018

BRIEF-Tyme Provides Update On At-The-Market Financing Activity

* TYME TECHNOLOGIES INC - HAS RAISED GROSS PROCEEDS OF APPROXIMATELY $5.0 MILLION FROM ITS AT-THE-MARKET FINANCING FACILITY Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Tyme reports encouraging efficacy and safety data from first human study of sm-88

* Tyme announces encouraging efficacy and safety data from first human study of sm-88 in women with metastatic breast cancer

06 Nov 2017

Earnings vs. Estimates